|View printer-friendly version|
|December 09, 2010 4:02 p.m.|
|Teva Announces Successful Results of Phase III Study with Oral Laquinimod For Multiple Sclerosis|
- Laquinimod study met primary endpoint of reducing annualized relapse rate Jerusalem, Israel, December 9, 2010 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) announced today initial results from the two-year Phase III ALLEGRO study, which demonstrated that relapsing-remitting multiple sclerosis (MS) patients treated with 0.6 mg daily oral laquinimod experienced a statistically significant reduction in annualized relapse rate compared to placebo. Additional clinical endpoints, including significant reduction in disability progression, as measured by Expanded Disability Severity Scale (EDSS), were also achieved.